(1Z)-N'-hydroxy-2-(3-pyridinyl)ethanimidamide | 261735-05-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: (1Z)-N'-hydroxy-2-(3-pyridinyl)ethanimidamide
• 英文别名: (Z)-3-Pyridylacetamidoxim；(1Z)-N'-hydroxy-2-pyridin-3-ylethanimidamide；(3-pyridyl)acetamidoxime；N'-Hydroxy-2-(pyridin-3-YL)ethanimidamide；N'-hydroxy-2-pyridin-3-ylethanimidamide
• CAS: 261735-05-1；348624-10-2；137499-45-7
• 化学式: C₇H₉N₃O
• mdl: MFCD05663234
• 分子量: 151.168
• InChiKey: ZEONASHSZKLJGT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  71.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (1Z)-N'-hydroxy-2-(3-pyridinyl)ethanimidamide 、 (2R)-2-[2-(tert-butoxy)-2-oxoethyl]-5-cyclohexylpentanoic acid 在 N-甲基吗啉 、 1-羟基苯并三唑一水物 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 反应 18.0h， 以835 mg的产率得到tert-butyl (3R)-3-[({[(Z)-1-amino-2-(3-pyridinyl)ethylidene]amino}oxy)carbonyl]-6-cyclohexylhexanoate
  参考文献：
  名称：

  Potent and Selective Nonpeptidic Inhibitors of Procollagen C-Proteinase

  摘要：

  6-Cyclohexyl-N-hydroxy-3-(1,2,4-oxadiazol-5-yl)hexanamides were previously disclosed as inhibitors of procollagen C-proteinase (PCP) culminating in the identification of amide 1. Our objective was to discover a second inhibitor that would have improved affinity for PCP and to optimize properties for transepidermal delivery (TED) to intact skin. Further investigation of this template identified a number of potent PCP inhibitors (IC50 values of 2-6 nM) with improved TED flux. Sulfonamide 56 had excellent PCP enzyme activity when measured with a peptide substrate (K-i 8.7 nM) or with the endogenous substrate procollagen (IC50 3.4 nM) and demonstrates excellent selectivity over MMPs involved in wound healing (> 10 000-fold). In the fibroplasia model, 56 inhibited deposition of insoluble collagen by 76 +/- 2% at 10 mu M and was very effective at penetrating human skin in vitro with a TED flux of 1.5 mu g/cm(2)/h, which compares favorably with values for agents that are known to penetrate skin well in vivo. Based on this profile, 56 (UK-421,045) was selected as a candidate for further preclinical evaluation as a topically applied, dermal anti-scarring agent.

  DOI：

  10.1021/jm061010z
• 作为产物：
  描述：

  3-吡啶乙腈 在 盐酸羟胺 、 sodium 作用下， 以 甲醇 为溶剂， 以100%的产率得到(1Z)-N'-hydroxy-2-(3-pyridinyl)ethanimidamide
  参考文献：
  名称：

  Use of naphthalene derivatives in treating lung carcinoma

  摘要：

  抑制人类小细胞肺癌细胞生长的方法包括向需要此类治疗的哺乳动物施用化合物的抑制细胞生长量，其化学式为##STR1##

  公开号：

  US05821245A1

文献信息

• [EN] HETEROCYCLIC DERIVATIVES AS GPCR RECEPTOR AGONISTS<br/>[FR] DERIVES HETEROCYCLIQUES UTILISES COMME AGONISTES DES RECEPTEURS GPCR
  申请人：PROSIDION LTD

  公开号：WO2005061489A1

  公开（公告）日：2005-07-07

  Compounds of Formula (I), R1-A-V-B-R2; or pharmaceutically acceptable salts thereof, are agonists of GPR116 and are useful as regulators of satiety, e.g. for the treatment of obesity, and for the treatment of diabetes.

  化合物的结构式（I），R1-A-V-B-R2；或其药学上可接受的盐，是GPR116的激动剂，可用作饱腹感的调节剂，例如用于肥胖症的治疗，以及糖尿病的治疗。
• Aryl and heteroaryl alkoxynaphthalene derivatives
  申请人：Pfizer Inc.

  公开号：US06166020A1

  公开（公告）日：2000-12-26

  Compounds of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.4, R.sup.23, R.sup.24, R.sup.25 and R.sup.26 are defined as in the specification. These compounds are useful psychotherapeutics and are potent serotonin (5-HT.sub.1) agonists and antagonists.

  化合物的化学式为##STR1##其中R.sup.1、R.sup.2、R.sup.4、R.sup.23、R.sup.24、R.sup.25和R.sup.26的定义如规范中所述。这些化合物是有用的心理治疗药物，是有效的5-羟色胺（5-HT.sub.1）激动剂和拮抗剂。
• Procollagen C-proteinase inhibitors
  申请人：——

  公开号：US20010021718A1

  公开（公告）日：2001-09-13

  1 and their salts, solvates, prodrugs, etc., wherein the substituents have the values mentioned herein, are Procollagen C-Proteinase (PCP) inhibitors and have utility in conditions mediated by PCP.

  它们及其盐、溶剂合物、前药等，其中取代基具有此处提及的值，是Procollagen C-蛋白酶（PCP）抑制剂，并在由PCP介导的疾病中具有用途。
• 3-Heterocyclylpropanohydroxamic acids
  申请人：——

  公开号：US20030119807A1

  公开（公告）日：2003-06-26

  Compound of formula (I): 1 and their salts, solvates, prodrugs, etc., wherein the substituents have the values mentioned herein, are Procollagen C-Proteinase (PCP) inhibitors and have utility in conditions mediated by PCP.

  化合物公式(I)的化合物及其盐、溶剂合物、前药等，在所述取代基具有所述数值的情况下，是前胶原C-蛋白酶（PCP）抑制剂，并在由PCP介导的疾病中具有应用价值。
• Ccr5 antagonists as therapeutic agents
  申请人：Kazmierski Mieczyslaw Wieslaw

  公开号：US20060229336A1

  公开（公告）日：2006-10-12

  The present invention relates to compounds of formula (I) or a pharmaceutically acceptable derivatives thereof, useful in the treatment of prophylazis of CCR5-related diseases and disorders, for example, in the inhibition of HIV replication, the prevention or treatment of HIV infection, and in the treatment of the resulting acquired immune deficiency syndrome (AIDS).

  本发明涉及式(I)化合物或其药学上可接受的衍生物，用于预防CCR5相关疾病和障碍的治疗，例如，抑制HIV复制，预防或治疗HIV感染，以及治疗由此产生的获得性免疫缺陷综合症（AIDS）。